AIM ImmunoTech Inc

ASE:AIM  
2.02
+0.05 (+2.54%)
Products

AIM Immunotech Submits Pre-Ind Application To FDA For Phase 2 Clinical Study Of Ampligen

Published: 09/08/2021 13:34 GMT
AIM ImmunoTech Inc (AIM) - Aim Immunotech Submits Pre-ind Application to the FDA for Phase 2 Clinical Study of Ampligen As a Potential Infusion Therapy for Post-covid-19 Cognitive Dysfunction.